In 2019, 262 million people worldwide had asthma, with 455,000 deaths from the chronic condition1, stark figures that highlight asthma control still needs improvement. Most people living with asthma believe that no physical symptoms mean their asthma is controlled, but this is sadly not always the case. Airway inflammation is the underlying cause of asthma, something that cannot be seen and not always felt.

Many asthma patients feel fine until they don’t. Objectively measuring airway inflammation with Fractional exhaled Nitric Oxide (FeNO) testing is a vital way to prevent exacerbations and improve overall asthma care.

Airway Inflammation Infographic - Advancements in FeNO Testing

What is FeNO and why does it matter2?

When airways are inflamed, they produce excess nitric oxide (NO), a gas that can be measured by performing a FeNO test. A FeNO test provides insight into a person’s airway inflammation by measuring NO levels in exhaled breath.

  • High FeNO levels indicate eosinophilic airway inflammation. The higher the reading, the more severe the inflammation is.

By measuring airway inflammation, healthcare professionals can use the results to aid an asthma diagnosis and tailor treatment appropriately.

Limitations of traditional asthma monitoring.

Taking a FeNO test with the NObreath - Advancements in FeNO Testing

Traditionally, clinicians have relied on patients relaying their symptoms, which doesn’t always give the full picture of a person’s asthma. Many people believe that because they have asthma, they should have a cough and they should have a wheeze, and they downplay their symptoms.

Providing a FeNO test at regular asthma reviews empowers healthcare professionals to detect airway inflammation early, allowing them to monitor medication response and personalise treatment. This ultimately can catch an exacerbation early and get patients back on track with well-controlled asthma.

Additionally, medication adherence rates range from 30% to 70%3. A patient may report taking their medication regularly and using the correct technique; however, a quick, easy FeNO test can reveal poor adherence. Showing a patient their airway inflammation can create an opportunity to discuss and reinforce the importance of good adherence and technique.

Recent advancements in FeNO testing.

NObreath device - Advancements in FeNO Testing

In the 1990s, researchers found that FeNO served as a non-invasive biomarker of airway inflammation and used chemiluminescence to measure it. This method proved very costly due to regular maintenance and calibration, and difficult to access because of the machines’ size and the specialist training required.

In recent years, this has advanced to electrochemical sensor technology, enabling more cost-effective, portable FeNO devices like the NObreath®, whilst still matching the gold-standard technology of chemiluminescence. Thanks to continuous innovation, FeNO devices are now accessible at the point of care and provide instant results, improving patient outcomes.

To learn more about chemiluminescence and electrochemical sensor technology, read our article here.

In the late 1990s, FeNO began to appear in international clinical practice guidelines for asthma, and the American Thoracic Society (ATS) officially recommended its use to assess airway inflammation in adults and children in 20114.

Since then, FeNO testing has been recommended in asthma guidelines across the world, with the most recent joint guidance from the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN), recommending FeNO as a first-line test for asthma diagnosis5.

To learn more about the global guidelines on asthma care and management, read our article here.

The NObreath® FeNO device

The NObreath® was developed in 2008, designed with healthcare professionals and patients in mind. It provides a non-invasive, fairly priced option for FeNO testing, making it more accessible to healthcare providers worldwide.

Featuring an adult and child test mode, the NObreath® is suitable for all settings thanks to its accuracy and portability. It requires an exhalation-only manoeuvre, making it a quick and easy test to take for both adults and children.

The device was designed with the patient in mind and features multiple flow incentive screens. These incentive screens not only engage the patient, but they also ensure a correct flow rate of 50 ml/s, providing an accurate test result.

To learn more about FeNO testing with the NObreath®, visit the website here.

Child test with the NObreath - Advancements in FeNO Testing

Many deaths from asthma are thought to be preventable, meaning better asthma care is needed. Advances in FeNO testing have been instrumental in improving asthma control, and with increasing recognition in global asthma guidelines, FeNO testing can make a difference.

To learn more about Bedfont® Scientific Limited, world leaders in breath analysis with over 49 years of expertise in the medical device industry, visit the website here.

References

  1. World Health Organization. Asthma [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
  2. NHS England. NHS Accelerated Access Collaborative» Fractional Exhaled Nitric Oxide (FeNO) [Internet]. www.england.nhs.uk. 2025. Available from: https://www.england.nhs.uk/aac/what-we-do/innovation-for-healthcare-inequalities-programme/rapid-uptake-products/fractional-exhaled-nitric-oxide/
  3. ‌Improving adherence in Asthma treatment | Cambridge Network [Internet]. Cambridgenetwork.co.uk. 2024. Available from: https://www.cambridgenetwork.co.uk/news/improving-adherence-asthma-treatment
  4. ‌Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American journal of respiratory and critical care medicine [Internet]. 2011;184(5):602–15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21885636/
  5. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245

Over 28 million people in the United States (US) have asthma1,2, with the condition named as the leading chronic disease in children, affecting approximately 4.9 million under the age of 182,3. In the US, asthma is one of the most common and costly diseases, and these stark figures highlight why asthma still matters, even in 2026. This Asthma and Allergy Awareness Month, we are exploring the prevalence of asthma and how advancing technology can make a difference.

Asthma and Allergy Awareness Month

Asthma places a significant burden on healthcare and the economy, with annual economic costs between 2008 and 2013 contributing to:

  • $3 billion in losses due to missed work and school days,
  • $29 billion due to asthma-related mortality,
  • $50.3 billion in medical costs.

The numbers prove that asthma is common, but it is important to remember that this chronic condition is also manageable; however, outcomes are not equal, and certain populations are disproportionately affected. These disparities are shaped by a combination of structural, social, biological, and behavioural factors. Structural inequities, such as5:

  • Systemic racism,
  • Residential segregation,
  • Discriminatory policies,

Often influence the conditions in which people live, work, and access care. These, in turn, affect social determinants like income, education, housing quality, environmental exposures, and access to healthcare. While biological factors such as genetics and individual behaviours like smoking or medication adherence play a role, it is these broader social and structural inequities that largely drive unequal asthma outcomes across populations.

The hidden problem: Poor asthma control

Millions of people are diagnosed with asthma, with many of them not having the condition well managed. It is estimated that 44% of children with asthma have uncontrolled asthma6, which can lead to exacerbations and severe asthma attacks.

Many asthma patients rely heavily on rescue inhalers, which relieve the immediate symptoms but do not address the underlying airway inflammation. This quick relief can make patients feel in control of their asthma, but without addressing the root cause, asthma remains uncontrolled beneath the surface.

Another contributor to poorly controlled asthma is misdiagnosis. Asthma is not a single condition; it can be allergic/eosinophilic or non-eosinophilic. If the asthma is not diagnosed correctly, this can lead to ineffective or over/under treatment. If the underlying asthma type isn’t properly diagnosed, the treatment cannot be matched to the disease type.

Additionally, a lack of objective measurement in routine care can affect asthma control. Traditionally, asthma management has relied on:

  • Symptoms,
  • Patient recall,
  • Peak flow.

The problem with just focusing on these points is that clinicians may over- or underestimate control, which leads to escalating or reducing treatment inappropriately. Symptoms do not always reflect underlying inflammation and may lead to missed opportunities for early intervention.

Better Asthma Care

This is where better access to objective, point-of-care tools, such as Fractional exhaled Nitric Oxide (FeNO) testing, is needed. Without objective measurement, asthma care often relies on what can be seen and heard, not on what’s happening at the inflammatory level inside.

What is FeNO testing7?

A FeNO test is a quick, easy, non-invasive way to measure airway inflammation, specifically eosinophilic inflammation. When airways are inflamed, higher levels of nitric oxide (NO) are produced. This gas can be detected in exhaled breath, with higher levels indicating inflammation, making FeNO testing a vital tool for asthma care and management.

FeNO Testing with the NObreath®

With FeNO providing a non-invasive, quick point-of-care test, it can help identify type 2 inflammation and predict steroid responsiveness, helping clinicians see inflammation that symptoms alone cannot reveal.

How FeNO improves decision-making

FeNO fits into the whole asthma pathway; it’s not just a diagnostic tool; it can also help treat and manage asthma. Diagnosing and managing this chronic condition isn’t always straightforward, and in the past, healthcare professionals have relied on guesswork. FeNO testing changes that, it can:

  • Support a diagnosis of asthma,
  • Guide inhaled corticosteroid (ICS) use,
  • Monitor medication adherence,
  • Predict exacerbation risk,
  • Reduce unnecessary medication escalation.
Child taking a FeNO test

FeNO is recognised in global guidelines for asthma care and management, with the ATS/ERS guidance positioning FeNO as a practical tool to support diagnosis, guide anti-inflammatory treatment, and monitor airway inflammation, helping clinicians move from symptom-based to more objective asthma care8.

Expanding access to FeNO testing

Objective testing has the potential to transform asthma care, but access remains a challenge. Limited availability outside specialist centres, time constraints in primary care, and geographic inequalities have all contributed to the underuse of tools such as FeNO. The result is a gap between what is possible and what is delivered in everyday care. Advances in technology only matter if people can access them.

Bedfont® Scientific Limited, an innovative MedTech company based in the UK with nearly 50 years of experience in medical breath analysis, has been improving asthma care and management worldwide for over 15 years with its NObreath® FeNO device. Working closely with its US distributor, coVita™, it has been working hard to improve access to FeNO testing by providing a fairly priced, low-maintenance FeNO device.

In 2025, the NObreath® became the allergists’ FeNO device of choice in the US, with Allergy Partners offering FeNO testing with the NObreath® through more than 125 locations in over 20 states. This partnership ensures that FeNO testing is being integrated into routine care, not just specialist settings, allowing more patients to get tested closer to home.

The future of asthma care

This Asthma and Allergy Awareness Month, we want to focus on how early intervention can lead to better long-term outcomes for asthma patients. Advances in technology mean that objective testing, such as FeNO, is more widely accessible, which is vital as biomarker-driven care becomes the standard. FeNO devices like the NObreath® provide clinicians with more insight into underlying inflammation that cannot be seen, enabling improved patient care.

To learn more about the NObreath® FeNO device and how it is improving precision in asthma care, visit the website here.

NObreath® FeNO device

References

  1. NCHS/DHIS. NHIS Adult Summary Health Statistics [Internet]. Cdc.gov. 2021. Available from: https://data.cdc.gov/National-Center-for-Health-Statistics/NHIS-Adult-Summary-Health-Statistics/25m4-6qqq/about_data
  2. ‌NCHS/DHIS. NHIS Child Summary Health Statistics [Internet]. Cdc.gov. 2021. Available from: https://data.cdc.gov/National-Center-for-Health-Statistics/NHIS-Child-Summary-Health-Statistics/wxz7-ekz9/about_data
  3. ‌Ferrante G, La Grutta S. The Burden of Pediatric Asthma. Frontiers in Pediatrics [Internet]. 2018 Jun 22;6(186):1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023992/
  4. ‌Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, 2008–2013. Annals of the American Thoracic Society [Internet]. 2018 Mar;15(3):348–56. Available from: https://pubmed.ncbi.nlm.nih.gov/29323930/
  5. ‌Asthma and Allergy Foundation of America. Asthma Disparities in America [Internet]. Asthma & Allergy Foundation of America. 2020. Available from: https://aafa.org/asthma-allergy-research/our-research/asthma-disparities-burden-on-minorities/
  6. ‌CDC Archives [Internet]. archive.cdc.gov. Available from: https://archive.cdc.gov/#/details?url=https://www.cdc.gov/asthma/asthma_stats/uncontrolled-asthma-children-2018-2020.htm
  7. ‌What is a FeNO Test? [Internet]. Aaaai.org. 2021. Available from: https://www.aaaai.org/Tools-for-the-Public/Conditions-Library/Asthma/What-Is-A-FeNO-Test
  8. ‌Murphy RC, Zhang P, Tejwani V, Khatri SB, Hallstrand TS, Ruminjo JK, et al. Summary for Clinicians: Clinical Practice Guideline for the Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma. Annals of the American Thoracic Society. 2022 Oct;19(10):1627–30.

Embedding compassion into policies, practices and everyday actions.

Bedfont® Scientific Ltd. is a world leader in breath analysis, with over 49 years of expertise in designing and manufacturing medical devices. The innovative med-tech company, based in Harrietsham, was proud to receive the Compassionate Workplace accreditation from Heart of Kent Hospice, in partnership with Compassionate Communities UK, in December 2025.

Compassionate Communities UK is a UK charity dedicated to embedding compassion into everyday life, including workplaces. The charity is collaborating with various organisations, helping employers ensure they operate in a compassionate way for staff who are dealing with bereavement, death and loss or those who may be facing a terminal illness themselves.

Heart of Kent Hospice, a charity-run hospice providing specialist palliative and end-of-life care for adults, as well as their families, carers and loved ones, is supporting employers in the local area with the tools and confidence to have compassionate conversations about end-of-life, loss and bereavement in the workplace. They were thrilled to have awarded Bedfont® with the Compassionate Workplace accreditation in December 2025.

David Dadswell, Corporate Partnerships Manager at Heart of Kent Hospice, said, “Bedfont’s commitment to becoming the first accredited Compassionate Workplace is a powerful statement. By recognising the realities of grief, caring and serious illness, they are setting a new standard for what a truly supportive employer looks like. Prioritising compassion at work will make a meaningful difference to their staff and families across our community.”

Having supported the hospice since 2023, sponsoring its flagship Bluebell Walk events and Shaun the Sheep trail, Bedfont® joined Heart of Kent Hospice for a roundtable discussion to identify areas where the hospice could provide support, such as signposting and delivering training. During the accreditation process, it was highlighted that some areas of the business required improvement, and the hospice subsequently delivered a group training session focused on those areas.

Compassionate Workplace

After completing the assessment, Bedfont® became the first business in Kent to achieve Compassionate Workplace status, underscoring the company’s commitment to providing an environment where every staff member feels valued, supported and heard.

“Receiving the Compassionate Workplace accreditation is a deeply meaningful milestone for us.” Said Jason Smith, CEO at Bedfont® Scientific. “As the first organisation in Kent to achieve this recognition, we feel both proud and responsible to lead by example. At the heart of our organisation are people, and we believe work should be a place of understanding, dignity and care, particularly during life’s most challenging moments. This accreditation strengthens our commitment to creating a culture where compassion is embedded in our leadership, our policies and our everyday actions.”

Already committed to employee wellbeing, Bedfont® has strengthened its offerings for staff, equipping them with the knowledge and tools to approach difficult conversations and support those dealing with bereavement or terminal illness.

To learn more about Bedfont® and its support of Heart of Kent Hospice, visit the website here, and follow them on LinkedIn.

Written by Dr Jafar Jafari, GI Cognition

This article reflects the opinions of a healthcare professional. The views expressed are their own. The intended use for the GastroCH4ECK® is to aid in the diagnosis of the following disorders:

  • Lactose Intolerance,
  • Small Intestinal Bacterial Overgrowth (SIBO).

Hydration and nutrition are often discussed as two separate topics. In reality, they work together every single day inside the digestive system. What we drink influences how comfortably we tolerate fibre, how easily our bowels move, and how efficiently our digestive system works. What we eat influences digestion, gas production, stool pattern, energy levels, and symptoms such as bloating or abdominal discomfort.

A simple way to think about this relationship is to imagine trying to mix ingredients in a completely dry container. Nothing moves properly. The contents simply sit there. Digestion works in a similar way: without adequate fluid, the digestive system struggles to move food smoothly through the gut. Hydration provides the medium in which digestion happens, while nutrition provides the materials the body, and the microbes in our gut, need to function.

But how do we know whether our gut is responding well to what we eat and drink? Interestingly, one of the most informative signals can come from something we rarely think about: our breath.

Your Breath as a “Thermometer” for the Gut1

One of the reasons I became so interested in hydrogen–methane breath testing (HMBT), and ultimately wrote a book about it The Essential Guide to Hydrogen and Methane Breath Testing, the book offers a unique window into how our digestive system is functioning.

Human tissues do not produce hydrogen or methane gases. These gases are produced when microorganisms in the gut ferment carbohydrates that escape digestion. Some of this gas enters the bloodstream and eventually reaches the lungs, where it is exhaled in our breath. By measuring hydrogen and methane in breath samples over time, clinicians can gain insight into microbial fermentation patterns in the gut.

In a way, breath testing acts like a thermometer for gut activity. Just as a thermometer shows how the body is responding to infection or inflammation, breath testing can reveal how gut microbes are responding to the food and drink we consume.

The interesting point is that this signal often appears much earlier than other markers of health. For example, nutritional deficiencies such as low iron or low vitamin B12 can take months or even years to develop before they are detected in blood tests. But changes in microbial fermentation can occur much more quickly, reflecting the daily interaction between diet, hydration, gut motility and microbial activity.

In that sense, microbial fermentation may provide one of the earliest signals that something in our digestive habits is not working well.

Why “Healthy Foods” Sometimes Cause Symptoms

One of the most common questions people ask is: “Why do I react to foods that are supposed to be healthy?”

  • The answer is surprisingly simple: healthy does not always mean symptom-free.

Foods such as fruit, beans, lentils, whole grains and many vegetables are rich in fibre and nutrients2. These foods are beneficial for long-term health and support the growth of beneficial microbes in the gut.

However, they are also fermentable. For people with slower gut movement, increased microbial activity in the small intestine, or heightened gut sensitivity, fermentation of these foods may produce more gas than the body comfortably tolerates1.

This does not mean those foods are harmful or should be permanently avoided. It simply means that digestion sometimes requires a more personalised approach, including attention to portion size, timing, food combinations and underlying digestive function. Understanding these patterns is where breath testing can sometimes be helpful.

Hydration: The Forgotten Partner of Fibre

Another question I frequently hear is whether drinking more water can help symptoms such as constipation or bloating. Hydration alone is rarely a complete solution, but it plays a crucial role in maintaining normal digestive function.

Adequate fluid intake supports healthy bowel movement and gut motility. When the body is dehydrated, the intestines absorb more water from the stool, making it harder and more difficult to pass.

Hydration also becomes particularly important when people increase fibre intake. Fibre and fluid work together. Increasing fibre rapidly without increasing fluid can sometimes make symptoms feel worse, especially in people with sensitive digestive systems.

For most adults, general NHS guidance suggests roughly 6 to 8 glasses of fluid per day3, though individual needs vary depending on activity level, environment and health status. A simple daily indicator of hydration is urine colour, pale yellow generally indicates adequate hydration3.

Another useful indicator of digestive health is the Bristol stool chart4, which describes stool consistency. It is a simple but surprisingly helpful way of monitoring how well the digestive system is functioning4.

These simple daily observations, hydration, stool pattern, and symptoms, can act as basic “thermometers” of gut health. Breath testing simply provides a more advanced version of this thermometer, offering deeper insight into microbial fermentation patterns, when the basic thermometers are not sufficient anymore1.

Why Testing Before Treatment Matters1

When people experience persistent digestive symptoms, they often feel tempted to experiment with probiotics, restrictive diets, or various supplements. Trying something new can feel proactive. However, in some situations this approach may not address the underlying cause and can occasionally make symptoms worse.

For example, if someone already has excessive microbial activity in the small intestine, adding more bacteria through probiotics may not always be beneficial. Similarly, eliminating large groups of foods without a clear reason can lead to unnecessary dietary restriction and reduced nutritional balance.

Restrictive diets may sometimes reduce symptoms temporarily, but they can also reduce the intake of important nutrients such as fibre, vitamins and minerals, all of which support long-term gut and overall health. In addition, overly restrictive eating patterns may deprive the beneficial microbes in the gut of the nutrients they rely on for their normal activity and balance.

A more rational approach is to test first, understand the underlying mechanism, and then treat accordingly. This is where tools such as hydrogen–methane breath testing can provide valuable information5,6.

Breath testing should always be interpreted carefully within the clinical context, to ensure accurate results5,6. It remains the only validated clinical test that provides a functional assessment of microbial fermentation activity in the gut1. Unlike many emerging microbiome analyses, which are currently not standardised or reliable enough to guide treatment decisions, breath testing can help identify patterns such as carbohydrate malabsorption, abnormal fermentation, or possible bacterial overgrowth when used appropriately.

These insights can guide more targeted management rather than trial-and-error approaches, especially, if you are really suffering from the symptoms.

A Note on IBS, Stress and Unexplained Symptoms7

Another important point is that conditions such as irritable bowel syndrome (IBS) must be considered as diagnoses of exclusion. In practice, this means that when major structural or inflammatory diseases have been ruled out, completely, then, symptoms may be grouped under the IBS label.

However, this does not mean the symptoms are imaginary or simply due to stress. While stress can influence gut function, it is often too simplistic to attribute persistent symptoms to psychological factors alone. In practice, almost any symptom can be linked to stress if we stop looking for other explanations! In the same way, many gut symptoms can quickly be labelled as IBS!

In many cases, subtle physiological mechanisms, such as altered gut motility, microbial fermentation, gut hypersensitivity, or food intolerance, may be contributing to symptoms even when routine tests appear normal1. Advances in gut physiology and microbiome research are gradually helping us understand these mechanisms better.

Practical Advice for Hydration and Nutrition Week

For Hydration and Nutrition Week, my message is simple.

  1. Drink fluids regularly throughout the day rather than all at once3.

Use urine colour as a simple guide to hydration.

  • Include fibre in your diet but increase it gradually to avoid developing symptoms2.

Use stool pattern as a simple guide to fibre intake.

  • If you have persisting symptoms despite eating and drinking well, consider whether there may be an underlying reason that deserves further investigation1.

Use Hydrogen-Methane Breath Test as a validated medical grade guide to the root causes.

Digestive symptoms are rarely random. The body always has a reason for them.

In everyday life we already use simple “thermometers” of gut health, urine colour can suggest hydration, and stool patterns can reflect gut movement. At a deeper level, hydrogen–methane breath testing can act as a functional thermometer of microbial activity and your diet in the gut1.

Sometimes, the answers to persistent digestive symptoms can be found not only in what we eat and drink, but also in what our breath quietly reveals about the inner workings of our gut.

This hydration and nutrition week, take control of your gut health. If you are experiencing persistent gut issues, consult a healthcare professional and ask about breath testing. Hydrogen and methane breath testing (HMBT) with devices like the Gastrolyzer® range offer a non-invasive insight into gut health and can aid investigation or diagnosis in a clinical setting or from the comfort of your own home.

To learn more about the Gastrolyzer® range, visit the website here. Dr Jafari’s book ‘The Essential Guide to Hydrogen and Methane Breath Testing’ covers HMBT in detail, if you would like to learn more visit the webpage here.

References:

  1. Jafari J. 2025. The Essential Guide to Hydrogen and Methane Breath Testing: The Modern Non-Invasive Approach to Investigating Gastrointestinal Disorders. Bedfont Scientific Ltd, United Kingdom.
  2. NHS. How to get more fibre into your diet. Available at: https://www.nhs.uk/live-well/eat-well/how-to-get-more-fibre-into-your-diet/ (Accessed: 16th March 2026).
  3. NHS. Water, drinks and your health. Available at:
    https://www.nhs.uk/live-well/eat-well/water-drinks-nutrition/ (Accessed: 16th March 2026).
  4. Yaseen S, Abuelass FK, kamaleldien mohamed Abuelass F. Improving Documentation of Bowel Movements Using the Bristol Stool Chart: A Quality Improvement Project in a District General Hospital in the United Kingdom. Cureus. 2026 Jan 6;18(1).
  5. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Official journal of the American College of Gastroenterology| ACG. 2017 May 1;112(5):775-84.
  6. Pimentel M, Saad RJ, Long MD, Rao SS. ACG clinical guideline: small intestinal bacterial overgrowth. Official journal of the American College of Gastroenterology| ACG. 2020 Feb 1;115(2):165-78.
  7. National Institute for Health and Care Excellence (NICE). Irritable bowel syndrome in adults: diagnosis and management (CG61). Available at: https://www.nice.org.uk/guidance/cg61 (Accessed: 16th March).

Shortlisting recognises Bedfont’s role in driving innovation and technology leadership across Kent.

Bedfont CTO Shortlisted at National Technology Awards

Scott Deamer-Smith, Chief Technology Officer (CTO) at Bedfont® Scientific Limited, has been recognised for his outstanding contribution to innovation and technology. Scott has spent an impressive 18 years of his career at Bedfont®, a med-tech company which specialises in the development of medical breath analysis devices and is thrilled to have been shortlisted in the Technology Leader of the Year category at this year’s National Technology Awards.

The awards are an annual UK programme hosted by National Technology News, designed to celebrate outstanding achievement and innovations in the technology sector. It spotlights companies, projects, products and leaders that drive technological progress and transformation across industries.

Scott Deamer-Smith, Chief Technology Officer at Bedfont® Scientific, comments, “I’m honoured to be recognised in the Technology Leader of the Year category and see it as a reflection of the strength of the team around me. At Bedfont®, innovation is something we create together every day, built on empowering people, encouraging curiosity & supporting bold ideas. This shortlisting represents the shared commitment & dedication of our technical team & the wider business. I’m incredibly proud of what we continue to accomplish together.”

To be considered in the Technology Leader of the Year category, individuals must demonstrate how they lead by example and inspire those around them to tackle the issues facing their business with innovative strategies and thoughtful staff development. Scott leads the technical department at Bedfont®, and its success is very much the result of his continued vision and commitment to driving technology development across the business.

“I count myself incredibly lucky to have seen Scott evolve since we were kids. Even back then, he was beating everyone in class with his technical prowess.” Said Jason Smith, CEO at Bedfont®. “Bedfont® has benefited enormously from his big brain, relentless curiosity and determination to push boundaries. If the judges manage to glean even a small part of the contribution he’s made, not just to our company, but to the wider industry, then there’s really only one winner.”

Bedfont®, a world leader in breath analysis, is incredibly proud of Scott’s achievement. The innovative med-tech company prides itself on staff development and actively encourages career growth with a dedicated training budget available to all staff. Scott joined Bedfont® in 2007 as an IT and Technical Support Engineer and, throughout his career at Bedfont®, has been given numerous opportunities to advance, culminating in his leadership of the technical department as Chief Technology Officer.

Winners will be announced at the awards ceremony on Thursday, 14th May at the London Marriott Hotel, where leading businesses and individuals will gather to celebrate this year’s outstanding achievements. To learn more about Bedfont® and its commitment to innovation, visit the website here.

Written by Melissa Dooley, GastroLife

This article reflects the opinions of a healthcare professional. The views expressed are their own. The intended use for the GastroCH4ECK® is to aid in the diagnosis of the following disorders:

Advancing the future of hydrogen-methane breath testing
  • Lactose Intolerance,
  • Small Intestinal Bacterial Overgrowth (SIBO).

Each year on the 29th of May, World Digestive Health Day highlights the importance of gastrointestinal wellbeing. It is also an opportunity to reflect on how innovation continues to improve the assessment of digestive disorders.

Over the past two years, I have contributed to Bedfont® Scientific’s World Digestive Health Day publications. In 2024, we explored the importance of structured investigation and the risks of self-diagnosis in digestive health1. In 2025, Bedfont® examined the science behind hydrogen-methane breath testing (HMBT)2 and its role in identifying small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption.

In 2026, we are looking at progress, for example, how HMBT has evolved, and how diagnostic technology such as the GastroCH₄ECK® is advancing non-invasive gut diagnostics.

The Evolution of HMBT

Historically, SIBO diagnosis relied on jejunal aspirate culture. This is an invasive, technically demanding, impractical procedure in routine care, and not cost-effective. Breath testing emerged as a patient-friendly test for diagnosing small intestinal bacterial overgrowth and carbohydrate malabsorption, though early adoption was limited by a lack of standardisation.

The publication of the North American Consensus in 2017 outlined recommendations around preparation protocols, substrate dosing and diagnostic thresholds.3 This was reinforced by the American College of Gastroenterology (ACG) Clinical Guideline in 2020, which formally recognised breath testing as a clinically appropriate tool in selected patients.4

These publications moved breath testing into a supported, structured diagnostic approach (provided that testing is carried out using recommended protocols, reliable analysers, and appropriately trained practitioners).

Standardisation in Clinical Practice

Breath testing literature highlights that HMBT must be performed according to recommended preparation protocols and interpreted in a clinical context.3

Importantly, device accuracy and reliability play a critical role in minimising variability. Advances in sensor technology and calibration systems have improved reproducibility across clinical settings, strengthening user confidence in breath testing as a diagnostic tool.

Expanding Access: Clinic and Home-Based Testing

Evidence suggests that home-based breath testing, when supported by appropriate testing instructions, can achieve high completion and reliability rates.5

This enables flexibility across both clinic-based workflows and home testing pathways, broadening access to diagnostic investigations while maintaining clinical confidence.

The following are some examples of commonly asked questions in relation to HMBT:

  • Is hydrogen-methane breath testing reliable for diagnosing SIBO?

When performed according to recommended protocols and interpreted alongside clinical assessment, breath testing is considered a valuable diagnostic tool

  • Why is methane measurement important?

Methane levels ≥ 10 ppm are indicative of intestinal methanogen overgrowth and are often linked to constipation-related symptoms.4 Measuring methane alongside hydrogen enhances diagnostic precision by identifying patients whose symptoms may not be explained by hydrogen-producing bacterial overgrowth alone.

  • What influences diagnostic accuracy?

Recent antibiotics, bowel prep, motility agents, and dietary non-compliance may affect results. Adherence to established protocols is very important.

Looking ahead, several important developments are expected to influence the next phase of breath testing:

  • Further international harmonisation of testing protocols, including guidance from organisations such as the British Society of Gastroenterology.6
  • Enhanced multi-gas detection capabilities, potentially expanding beyond hydrogen and methane.
  • Greater precision in patient selection, improving cost-effectiveness and clinical outcomes.

Conclusion:

HMBT has evolved to a structured, consensus-supported diagnostic tool. Advances in clinical understanding, combined with ongoing innovation in diagnostic technology, have strengthened its role in assessing SIBO, IMO, and carbohydrate malabsorption.

As we mark World Digestive Health Day 2026, continued innovation will remain central to advancing digestive healthcare worldwide.

Gastrolyzer® range of HMBT devices:

The Gastrolyzer® range of devices, comprising the Gastro+™ hydrogen breath testing device and the GastroCH4ECK® have been helping to detect gastrointestinal disorders for over 30 years.

Advancing the future of hydrogen-methane breath testing

The Gastro+™ is a portable, handheld hydrogen device for quick, easy breath analysis. Tests can be conducted with a mouthpiece or a facemask for infants or elderly patients who struggle to hold their breath.

The GastroCH4ECK® is the only HMBT device with direct breath testing, allowing you to take a reading on the spot with instant results. It also offers remote testing by collecting breath samples in a breath bag for analysis at a later date.

The Gastrolyzer® range helps to streamline workflows in clinics and guide treatment decisions effectively. To learn more about the Gastrolyzer®, visit the educational portal here.

References:

  1. Bedfont® Scientific (2024) ‘World Digestive Health Day 2024: Taking control of your digestive health – importance of not self-diagnosing’. Available at: https://www.bedfont.com/world-digestive-day-understanding-gut-health-and-the-power-of-hmbt/ (Accessed: 23rd February 2026)
  2. Bedfont® Scientific (2025) ‘World Digestive Day: Understanding gut health and the power of HMBT’. Available at: https://www.bedfont.com/world-digestive-day-understanding-gut-health-and-the-power-of-hmbt/ (Accessed: 23rd February 2026)
  3. Rezaie, A., Buresi, M., Lembo, A. et al. (2017) ‘Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus’, The American Journal of Gastroenterology, 112(5) pp 775–784
  4. Pimentel, M., Saad, R.J., et al (2020) ‘ACG clinical guideline: small intestinal bacterial overgrowth’, The American Journal of Gastroenterology, 115(2), pp. 165–178
  5. Pitcher, C. et al. (2022) ‘Hydrogen and Methane Breath Tests can be performed by patients independently at home with >95 % success rate’, Available at: https://gut.bmj.com/content/71/Suppl_1/A185.2 (Accessed: 24 February 2026).
  6. British Society of Gastroenterology (BSG) ‘AGIP protocol for hydrogen and methane breath testing’. Available at: https://www.bsg.org.uk/clinical-resource/agip-protocol-for-hydrogen-methane-breath-testing (Accessed: 26th February 2026).

A collective community effort helps breathe new life into a much-loved school space.

Bedfont® Scientific Limited, a local med-tech business located in Harrietsham, was pleased to help create a tranquil woodland-themed library for children at Harrietsham Church of England Primary School. The library space, which had been used as a flow-through area with no real purpose until 2 years ago, was created for children to enjoy during lunchtime; however, it lacked a certain magic. With tight educational budgets, the school asked for help and set out to revamp the school library.

When the school reached out to local businesses for support in revitalising its library, Bedfont® was proud to step forward. Over a couple of weeks, a dedicated team of Bedfont® volunteers worked side by side with school staff and family members to transform the space with a fresh coat of paint. The collaborative effort not only refreshed the physical environment but also helped create a brighter, more welcoming space that inspires students and encourages a love of reading.

“The physical environment plays a significant role in supporting young people’s wellbeing,” said Claire Dadswell, Wellbeing Manager at Bedfont®. “By helping to refresh the library, we’ve contributed to a space that encourages creativity, focus and a love of reading. It’s wonderful to know that students will benefit from this transformation for years to come.”

Bedfont® Supports School Library Revamp
Bedfont® supports school library revamp

Much of the library’s transformation was made possible through generous community support. The furniture was kindly donated by a library that was closing its doors, while the greenery used to bring the woodland theme to life was provided by online retailer Blooming Artificial. After discovering a striking feature tree on Facebook Marketplace, the school organised a ‘Wear It Green Day’ to raise the funds needed to purchase it. Additional proceeds from the school’s summer fundraiser, ‘HotDogs and Cool Music’, helped to fund the Accelerated Reader programme.

Staff and parents also volunteered to scan and label the library’s collection, while additional items, including the astroturf, were sourced through donations from the local community via Facebook Marketplace.

Jackie Chambers, Head Teacher at Harrietsham Primary School, said, “The school are extremely grateful for the very kind support of Bedfont® and the other members of our local community who have supported us with our library revamp.  They have really helped to bring the children’s vision for their new library to life.  Our thanks also to the staff who have helped and to Mr Walker and Mrs Mannering for their vision and hard work with this project.  This joint project has meant that our children now have the most magical and engaging space to enjoy reading.”

Supporting local initiatives is a key part of Bedfont’s commitment to community engagement, and the company was delighted to contribute to a project that will benefit pupils for many years. To learn more about Bedfont® and its community commitments, visit the website here.

Bedfont® appoints Michael Bencak to strengthen its position and accelerate growth.

Bedfont® Scientific Ltd., a world leader in breath analysis, has been designing and manufacturing medical breath analysis devices for almost 50 years and has seen significant growth over the past decade. The innovative med-tech company is pleased to add further experience to its board of directors with the appointment of Michael Bencak. Michael has over 20 years of experience building and leading companies in the global life science and healthcare industries. His strategic approach helps businesses unlock their potential growth and lead them through international expansion.

Bedfont® appoints Michael Bencak
Michael Bencak

Bedfont® works with healthcare professionals worldwide to provide cutting-edge breath analysis medical products to the highest standard, through technical innovation and professional business practice. Working with over 100 distributors worldwide, Bedfont® is leading the way in breath analysis, thanks to its innovative non-invasive devices that aid diagnosis and investigations, ultimately improving patient care worldwide.

“We are delighted to announce the appointment of Michael Bencak to the Board of Bedfont® Scientific Ltd. Michael brings a wealth of international experience in the medical device and life sciences sectors, with a strong track record of scaling businesses, building global partnerships, and driving strategic growth. His insight and leadership will be invaluable as Bedfont® continues its mission to advance breath analysis technology and improve patient care worldwide.” Said Jason Smith, CEO at Bedfont®, “As we enter an exciting new phase of growth, Michael’s appointment strengthens our Board and supports our long-term strategy to expand Bedfont’s global impact in respiratory diagnostics and beyond. Please join us in welcoming Michael to the Bedfont® Board.”

With Keensight’s acquisition of a majority stake in the business back in 2025, the addition of Michael’s experience can only accelerate Bedfont’s growth and move it closer to a world where everyone has access to instant, non-invasive, simple breath testing to aid medical diagnosis.

To learn more about Bedfont® and how it is improving accessibility and healthcare standards worldwide, visit the website here.

The NObreath® FeNO device offers a clear pathway to more effective asthma care, reducing over-reliance on blue inhalers.

Bedfont® Scientific Limited, an innovative med-tech company specialising in medical breath analysis devices, welcomes the new study at University Hospital Southampton exploring whether enhanced asthma check-ups can reduce inhaler use among children. For over 15 years, Bedfont® has supported improved asthma care with its NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which measures airway inflammation through exhaled breath. The quick and easy test provides clinicians with objective insight to guide medication decisions, reduce unnecessary reliever prescriptions, prevent over-reliance on blue inhalers, and help avoid future asthma attacks.

Research has found that children using 6 or more blue reliever inhalers a year are 3-5 times more likely to have an asthma attack1. Reliever inhalers only treat the immediate symptoms and mask the underlying airway inflammation, which can lead to further exacerbations.

The study aims to create a new alert system that automatically notifies general practitioners (GPs) when a child has been prescribed too many inhalers, prompting an immediate check-up. This will allow healthcare professionals to perform a review and help prevent future attacks.

Jason Smith, CEO at Bedfont®, comments, “We welcome the focus this important study brings to the growing problem of reliever inhaler over-use in children, a clear signal that many young people are still not getting the right support for long-term asthma control. Over-reliance on blue inhalers often reflects unmanaged airway inflammation and missed opportunities for targeted treatment. That’s why we continue to advocate for improving the accessibility of FeNO testing in primary care, a guideline-recommended, evidence-based tool that helps clinicians identify and treat underlying inflammation early. With better access to FeNO testing across the UK, we can help reduce unnecessary reliever use, improve outcomes for children, and support GPs in delivering truly personalised asthma care.”

Although FeNO testing is now recommended as a first-line test in UK asthma guidelines, access remains inconsistent across primary care. As a result, many children continue to be managed without the benefit of objective airway inflammation testing, increasing the risk of poorly controlled asthma and over-reliance on reliever inhalers. Reliever inhaler overuse in children is a well-recognised marker of uncontrolled asthma and is associated with a higher risk of exacerbations and emergency admissions.

NObreath Offers Asthma Pathway

Greater investment and targeted funding are urgently needed to support the widespread adoption of FeNO technology in primary care, helping clinicians deliver earlier, more accurate diagnoses and reduce preventable harm. To learn more about the NObreath® and how it can help asthma care and management, visit the website here.

References

  1. News I. Southampton researchers lead UK-first study to target “dangerous” asthma inhaler overuse [Internet]. ITV News. 2026 [cited 2026 Mar 3]. Available from: https://www.itv.com/news/meridian/2026-02-25/uk-first-study-targets-dangerous-overuse-of-asthma-inhalers-in-children

Bedfont® Scientific Limited believes balanced teams drive better decision-making, stronger innovation, and long-term success.

Bedfont® Scientific Limited, a well-established Med-Tech company with over 49 years of expertise in the design and manufacture of medical breath analysis devices, is celebrating the women driving innovation in the Med-Tech industry this International Women’s Day (IWD). IWD is an annual event that celebrates women’s achievements and raises awareness about gender equality. In 2026, IWD celebrates 115 years of raising awareness of discrimination and taking action to forge gender parity.

International Women's Day 2026

This year’s theme, ‘Give to gain’, highlights the power of reciprocity and support. By giving women equal access to leadership opportunities, Bedfont® has built a diverse and balanced team. Today, women make up 50% of the workforce and nearly half of the companies’ 18 managers, proof that inclusion creates tangible gains for people and performance alike.

Switzerland is leading the way in Med-Tech, with women accounting for 40% of the industry’s workforce1. However, research published in 2024 shows that among the 78 largest medical device companies in Europe, only 24.4% of leadership positions are held by women2, highlighting the ongoing need for greater gender equality at senior levels.

“In a world where women in business have far greater opportunities than in our ancestors’ time, we are now seeing women actively driving the future of MedTech through innovation, leadership and scientific excellence. I am incredibly proud that nearly half of the leadership team at Bedfont are women, clear evidence that inclusion fuels both performance and progress. Representation matters, not only within our industry but for the next generation watching.” Comments Natasha Smith, Chief Operating Director at Bedfont®. “As a mother of two daughters, I want them to grow up proud, strong and confident enough to make their own mark in science, technology and beyond. On this International Women’s Day, with this year’s theme “Give to Gain,” we recognise that by investing in, training and championing women, we are shaping the future of MedTech and creating lasting impact for generations to come.”

This International Women’s Day, Bedfont® is celebrating the strength of a balanced workforce by recognising the women across the organisation with sustainably sourced chocolate from local business N2 Sweets Lab. This initiative reflects the company’s broader commitment to sustainability while supporting both local businesses and third-party partners worldwide, reinforcing a give-to-gain approach that benefits people, communities, and the planet.

To learn more about Bedfont® and its commitment to improving healthcare worldwide, visit the website here.

References

  1. Medtech Sector Study 2024 [Internet]. Swiss Medtech. 2024. Available from: https://www.swiss-medtech.ch/en/news/medtech-sector-study-2024
  2. Kirsh D. Women gain ground in medtech leadership, but parity remains far off [Internet]. Medical Design and Outsourcing. 2025 [cited 2026 Feb 10]. Available from: https://www.medicaldesignandoutsourcing.com/women-gain-ground-in-medtech-leadership-but-parity-remains-far-off/
Back to top